Trial title not recorded
Lung Cancer · Esophageal Cancer · Mesothelioma · Gastrointestinal Neoplasms · Breast Cancer
Enrolment: 16 · Results not recorded
Loading the evidence…
Drug · DNA inhibitor
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Lung Cancer · Esophageal Cancer · Mesothelioma · Gastrointestinal Neoplasms · Breast Cancer
Enrolment: 16 · Results not recorded
Ewing Sarcoma · Sarcoma
Enrolment: 8 · Results not recorded
Esophageal Neoplasms · Lung Neoplasms · Mesothelioma · Thymus Neoplasms · Neoplasms, Germ Cell and Embryonal
Enrolment: 3 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Moderate controlled cortical impact over the left parietal cortex at 6 m/s with 2 mm deformation depth, plus rat primary neuron cultures
Mithramycin was strongly neuroprotective against DNA-damage-dependent neuronal death in vitro, but after controlled cortical impact it reduced fodrin cleavage and phospho-c-Jun only, with markers of p53-dependent apoptosis showing non-significant trends.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
Model: circumferential thermal oesophageal burn injury
Topical mithramycin-A delivered by a dissolvable stent reduced submucosal collagen deposition after oesophageal burn injury.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.